Seagen Inc.

Headquarters: Bothell, WA, United States

Founded: 1997

Employees: 2,675

CEO: Dr. Clay B. Siegall


Market Cap

$43.15 Billion

USD as of Dec. 1, 2023

history Market Cap History

Seagen Inc. market capitalization over time

Evolution of Seagen Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Seagen Inc.

Detailed Description

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Top 1-year algo backtest: +240.10%

$10,000 in February 2023 would now be $34,010 by following it 5 minutes per day at market close.

How much did you gain in the last 12 months?

Stocks & Indices

Seagen Inc. has the following listings and related stock indices.

Stock: NASDAQ: SGEN wb_incandescent

Stock: FSX: SGT wb_incandescent

Product & Services

Brentuximab vedotin and other antibody-drug conjugates

Key People

Clay B. Siegall Ph. D (Chairman, President & CEO) Todd E. Simpson (CFO) Jean Liu (Executive Vice President Legal Affairs, General Counsel, Corporate Secretary) Jonathan Drachman M. D. (Chief Medical Officer and Executive Vice President of R& D) Vaughn Himes (Executive Vice President) Technical Operations and Process Sciences Charles Romp (Senior Vice President) Sales Felix Baker Lead Independent Director Pinkston Peggy Senior Director Corporate Communications


Revenue: 2.176 Billion(2020)



Building 3

21717 30th Drive S.E

Bothell, WA 98021

United States

Phone: 425 527 4000